

Product datasheet for RC223937L3V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

CTDSPL (NM_001008392) Human Tagged ORF Clone Lentiviral Particle

Product data:

Product Type: Lentiviral Particles

Product Name: CTDSPL (NM_001008392) Human Tagged ORF Clone Lentiviral Particle

Symbol: CTDSPL

Synonyms: C3orf8; HYA22; PSR1; RBSP3; SCP3

Mammalian Cell

Selection:

Puromycin

Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092)

Tag: Myc-DDK

ACCN: NM_001008392

ORF Size: 828 bp

ORF Nucleotide

OTI Disclaimer:

The ORF insert of this clone is exactly the same as(RC223937).

Sequence:

The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing

variants is recommended prior to use. More info

OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression

varies depending on the nature of the gene.

RefSeg: NM 001008392.1

 RefSeq Size:
 4455 bp

 RefSeq ORF:
 831 bp

 Locus ID:
 10217

 UniProt ID:
 015194

 Cytogenetics:
 3p22.2

Protein Families: Druggable Genome, Phosphatase

MW: 30.9 kDa







Gene Summary:

Recruited by REST to neuronal genes that contain RE-1 elements, leading to neuronal gene silencing in non-neuronal cells (By similarity). Preferentially catalyzes the dephosphorylation of 'Ser-5' within the tandem 7 residue repeats in the C-terminal domain (CTD) of the largest RNA polymerase II subunit POLR2A. Negatively regulates RNA polymerase II transcription, possibly by controlling the transition from initiation/capping to processive transcript elongation.[UniProtKB/Swiss-Prot Function]